The mammalian ionotropic glutamate receptor family encodes 18 gene products that
coassemble to form ligand-gated ion channels containing an agonist recognition site, a …

Schizophrenia is a severe mental disorder associated with a characteristic constellation of
symptoms and neurocognitive deficits. At present, etiological mechanisms remain relatively …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

N‐methyl‐D‐aspartate receptors (NMDARs) are ion channels gated by glutamate, the major
excitatory neurotransmitter in the mammalian central nervous system (CNS). They are …

Glycine transporters are endogenous regulators of the dual functions of glycine, which acts
as a classical inhibitory neurotransmitter at glycinergic synapses and as a modulator of …

BACKGROUND: D-serine is an allosteric modulator of the brain N-methyl-d-aspartate
(NMDA) receptor and a potential novel treatment of schizophrenia. Double-blind studies …

Pharmacotherapy of schizophrenia based on the dopamine hypothesis remains
unsatisfactory for the negative and cognitive symptoms of the disease. Enhancing N-methyl …

Dopamine D 2 receptor antagonism is a unifying property of all antipsychotic drugs in use for
schizophrenia. While often effective at ameliorating psychosis, these drugs are largely …

Translational control depends on phosphorylation of eIF2α by PKR-like ER kinase (PERK).
To examine the role of PERK in cognitive function, we selectively disrupted PERK …

Recent evidence indicates that enhancing N-methyl-d-aspartate (NMDA) neurotransmission
with the treatment of NMDA/glycine site agonists, such as d-serine, or a glycine transporter-1 …